LEXICON
No.105 March 12, 2012

Drug marketing license (authorization) holder; drug marketer
医薬品製造販売業者
First-class drug marketing license (authorization) holder; first-class drug marketer
第1種医薬品製造販売業者
Second-class drug marketing license (authorization) holder; second-class drug marketer
第2種医薬品製造販売業者

The Pharmaceutical Affairs Law (PAL;薬事法) which went into effect in April 2005 separated drug manufacturing (製造) from marketing (製造販売), allowing companies without their own manufacturing facilities (製造設備) to market drugs manufactured by other companies (manufacturing license holders;製造業者). Drug marketing license...

To read the full story

LEXICON

By Philip Carrigan

Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…

By Yoshinori Sagehashi

Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…

Members of a health ministry panel on pharmaceutical regulations on February 8 broadly agreed on a proposal to allow regulatory…

By Izuru Ando

Generic manufacturers in Japan will be required to disclose supply-related information from this June under a new company indicator rule…

The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…